Clinicopathological Profiles Associated with Discordant IRAS/I Mutational Status between Liquid and Tissue Biopsies in a Real-World Cohort of Metastatic Colorectal Cancer

• Published in: Cancers Vol. 15; no. 14
• Main Authors: Brozos-Vázquez, Elena, Lago-Lestón, Ramón Manuel, Covela, Marta, de la Cámara Gómez, Juan, Fernández-Montes, Ana, Candamio, Sonia, Vidal, Yolanda, Vázquez, Francisca, Abalo, Alicia, López, Rosa, Blanco, Cristina, Muinelo-Romay, Laura, Ferreirós-Vidal, Isabel, López-López, Rafael
• Format: Journal Article
• Language: English
• Published: MDPI AG 01-07-2023
• Subjects: Analysis; Colorectal cancer; Genetic aspects; Health aspects; Liver; Metastasis; Panitumumab; Pharmaceutical industry; United States; Spain
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15143578

The evaluation of RAS mutations from plasma circulating tumour DNA (ctDNA) has emerged as an efficient approach to guide therapeutic decisions in the treatment of metastatic colorectal cancer (mCRC). However, disagreements about the RAS mutational status in tests using liquid and tumour tissue biopsies can lead to misinterpretation of the tumour genotype and compromise effective therapy. We used digital droplet PCR (ddPCR) technology and logistic regression models to decipher the clinicopathological profiles that commonly influence the levels and detection of plasmatic RAS mutations and are associated with discordant assays. The absence of liver metastases and the resection of the primary tumour were associated with reduced ctDNA levels and low percentages of positive agreement between tissue and ctDNA tests, predominantly when the mCRC originated in the right colon and rectum. Thus, ctDNA assays reporting undetected RAS mutations in these patients should be taken prudently, and further investigations should be considered before any decision about treatment. We aimed to identify common mCRC profiles associated with a discordant mutational status of RAS between the standard of care (SoC) tumour tissue tests and ctDNA tests to understand ctDNA detection and improve treatment responses. This was a multicentre, retrospective and prospective study. A total of 366 Spanish mCRC patients were independently recruited. BEAMing ddPCR technology was employed to detect ctDNA RAS mutations, and logistic regression analyses were performed to investigate clinicopathological factors associated with discordance. The highest concordance ratios were observed in profiles with multiple metastatic sites when the liver was present (89.7%; 95% CI 84.8–93.2), profiles with synchronous disease without primary tumour resection (90.2%; 95% CI 83.6–94.3) and profiles with mCRC originating in the left colon (91.3%; 95% CI 85.0–95.0). Metachronous disease originating in the right colon (OR = 6.1; 95% CI 1.7–26.5; p-value = 0.006) or rectum (OR = 5.0; 95% CI 1.5–17.8; p-value = 0.009) showed the highest probability of discrepancies. Primary tumour resection and a higher frequency of single metastases in the peritoneum or lungs in these patients were associated with reduced plasmatic mutation allele fractions (MAFs) and an increased probability of showing false-negative genotypes. Additional testing of patients with mCRC originating in the right colon or rectum with a single non-mutated ctDNA test is advised before the choice of therapy.